Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3873737 | 0.89 | SMN1; SMN2 (0.53) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL13897663 | 0.87 | MEN1 (0.50) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL13648657 | 0.84 | ALK (0.52) | MAPTRAB9ANPC1AURKAMEN1 | |
| SCHEMBL14498989 | 0.84 | CDK2 (0.64) | MAPTRAB9ANPC1GSK3BAURKA | |
| SCHEMBL3873336 | 0.84 | MEN1 (0.57) | MAPTGSK3BAURKAGSK3AMEN1 | |
| SCHEMBL3865571 | 0.83 | PTK2 (0.49) | MAPK1GSK3BAURKAGSK3APTK2B | |
| SCHEMBL5417832 | 0.81 | STK17A (0.68) | MAPTNPC1MAPK1GSK3BAURKA | |
| SCHEMBL13898388 | 0.80 | MEN1 (0.53) | MAPTGSK3BAURKAGSK3AMEN1 | |
| SCHEMBL1918937 | 0.77 | STK17A (0.61) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL3869070 | 0.76 | GSK3B (0.53) | MAPTMAPK1GSK3BAURKAGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | claimed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | MAPT 2578/4885RAB9A 1508/4885NPC1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.